Navigation Links
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Date:8/29/2010

>Medical Pharmaceuticals, Clinical Trials & Medical Discoveries Click to view news release full screen  

Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients

 

PARIS, August 30, 2010 /PRNewswire-FirstCall/ --

- First Results From the TEMSO Phase III Trial to be Presented During the ECTRIMS Congress in October 2010

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational once-daily oral drug teriflunomide significantly reduced annualized relapse rate (ARR) at 2 years versus placebo in patients with relapsing multiple sclerosis (RMS), thus achieving the primary endpoint in the TEMSO phase III trial. Both the 7mg and 14mg doses of teriflunomide were well tolerated with a similar number of patients reporting either treatment-emergent adverse events (TEAEs) or TEAEs leading to treatment discontinuation in the treatment arms versus placebo.

Effects on other clinical and MRI related outcomes further support the primary outcome. The safety profile was in line with previous clinical experience.

The TEMSO trial is the first study of a large phase III clinical development program to produce results on teriflunomide as monotherapy. Study findings from TEMSO will be presented during the platform presentation scheduled for October 15, 2010, starting at 9:15 a.m. CET at the 26th Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Gothenburg, Sweden. The TEMSO study results are embargoed until this oral presentation
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
2. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
3. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
4. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
5. Study Shows Machine Perfusion Significantly Improves Transplant Results
6. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
7. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
8. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
9. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
10. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
11. Buehler Motor, Inc., Significantly Expands Customer and Partner Support in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , Sept. 3, 2015 /PRNewswire/ - bioLytical Laboratories Inc., ... announce its study " Sensitivity of a rapid point ... enhanced by its affinity for HIV gp41 IgM antibodies ... Virology.  This study highlights INSTI,s ability to detect early ... findings at the 8 th annual International AIDS ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... If you ... in Boston this October, you will also want to sign up for the ... October 18th. The tour includes a walk through of the (8) chemistry teaching ...
(Date:9/2/2015)... -- Research and Markets ( ... PharmaBiotech,s new report "Biochips and Microarrays - ... This report is an analysis of ... report starts with a description of technologies as ... array comparative genomic hybridization (CGH), copy number variation ...
(Date:9/2/2015)... Virginia , September 2, 2015 ... of the winners of the 2015 BeHEARD science challenge, ... that offers rare disease researchers, access to the latest ... use its drug repositioning and pathway analytics capability to ... Wylder Nation Foundation in the study of Niemann-Pick Disease ...
Breaking Biology Technology:bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 2bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 3Erlab Invites You to Tour the Largest Installation of Filtered Fume Hoods in the World 2Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2
... press release is available in German . ... be no longer useless or even a problem. On the ... easily or to store data more efficiently! These are two ... made at the Physikalisch-Technische Bundesanstalt (PTB). This so-called "thermoelectric voltage" ...
... 2011 Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX ), ... for the company,s third quarter ended September 30, 2011 will ... 2011. The Pacira management team will host a conference call ... developments on Monday, Oct. 31, 2011 at 9 a.m. ET. ...
... Mexico, Oct. 24, 2011 Synthetic Genomics Inc. (SGI), ... solutions to a variety of markets including biofuels, biochemicals, ... C.V., a Mexico based investing and management company with ... agribusiness, have announced the formation of a new company, ...
Cached Biology Technology:Magnetic nanoswitch for thermoelectric voltages 2Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call 2Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call 3Synthetic Genomics Inc. and Plenus, S.A. de C.V. Form New Sustainable Agriculture Company, Agradis, Inc. to Develop and Commercialize Products Using Genomic Technologies 2Synthetic Genomics Inc. and Plenus, S.A. de C.V. Form New Sustainable Agriculture Company, Agradis, Inc. to Develop and Commercialize Products Using Genomic Technologies 3Synthetic Genomics Inc. and Plenus, S.A. de C.V. Form New Sustainable Agriculture Company, Agradis, Inc. to Develop and Commercialize Products Using Genomic Technologies 4Synthetic Genomics Inc. and Plenus, S.A. de C.V. Form New Sustainable Agriculture Company, Agradis, Inc. to Develop and Commercialize Products Using Genomic Technologies 5
(Date:8/12/2015)... 12, 2015 As the digital ... innovation and advanced biometrics technology is accelerating beyond expectations.  ... rely on using their credit cards, the digital currency, ... for payment services led by companies in the space ... Google, Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ...
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, featuring FPC,s touch ... 2015 that relate to sales of FPC1155 for this smartphone model ... for 2015. Jörgen Lantto, CEO of FPC, comments: " ... manufacturer in China and we are proud ... for Z1 , its first ...
(Date:8/6/2015)... 6, 2015  Today, U.S. Congressman Mike ... ™ to learn firsthand how Silicon Valley technologies ... is a world leader in multi-factor identity management ... helping federal agencies and commercial organizations achieve new ... "The vast majority of network breaches can ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Rep. Honda to Visit Crossmatch in Redwood City 2
... in the adult brain is well known. It is what ... lateral ventricles. This is where neural or brain stem cells ... For many years now, the subventricular zone has been suspected ... gliomas, the most deadly type of which is glioblastoma. ...
... plants and animals alike. When cells are deprived of water, ... a medium, chemicals and enzymes inside the cells may malfunction. ... Polypodium polypodioides ), can survive extreme measures of water loss, ... do the cells in these desiccation-tolerant plants remain viable? ...
... release is available in Spanish . , ... project to fine-tune computer models that can indicate when ... The results will help pinpoint the effectiveness of trees ... temperatures and global climate change. ARS ...
Cached Biology News:Brain tumors: Tissue stem cell turning into tumor stem cell 2Bringing dehydrated plants 'back to life' 2Bringing dehydrated plants 'back to life' 3Model predicts shifts in carbon absorption by forest canopies 2